Thomas B. Casale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas B. Casale has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Harold S. Nelson
4 shared publicationsJeffrey R. Stokes
Division of Allergy and Immunology, Creighton University, Omaha, Nebraska
4 shared publicationsFrancisco A. Romero
2 shared publicationsLinda Cox
President, American Academy of Allergy, Asthma, and Immunology (AAAAI), Milwaukee, Wis
2 shared publicationsAbdo Berro
Department of Medicine, Creighton University Medical Center
1 shared publicationAdam Asare
1 shared publication
Latest Publications
- 9 March 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 131 (1) , 6-8
Is it time to set the alarmins as potential targets in food allergy?
- 9 March 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 131 (1) , 6-8
Is it time to set the alarmins as potential targets in food allergy?
- 1 August 2016
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 117 (2) , 121-125
Characterization of asthma endotypes: implications for therapy
- 1 August 2016
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 117 (2) , 121-125
Characterization of asthma endotypes: implications for therapy
- 1 September 2013
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 1 (5) , 455-457
Allergy Immunotherapy Safety: Location Matters!
- 1 September 2013
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 1 (5) , 455-457
Allergy Immunotherapy Safety: Location Matters!
- Open Access
- 8 October 2012
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 172 (18) , 1365-1375
Long-Acting β2-Agonist Step-off in Patients With Controlled Asthma
Review from JAMA Internal Medicine — Long-Acting β2-Agonist Step-off in Patients With Controlled Asthma — Systematic Review With Meta-analysis
- 8 October 2012
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 172 (18) , 1365-1375
Open AccessLong-Acting β2-Agonist Step-off in Patients With Controlled Asthma
Review from JAMA Internal Medicine — Long-Acting β2-Agonist Step-off in Patients With Controlled Asthma — Systematic Review With Meta-analysis
- 1 November 2011
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 45 (5) , 1084-1089
Expression and Function of a Novel Variant of Estrogen Receptor–α36 in Murine Airways
Evidence suggests that estrogen signaling is involved in sex differences in the prevalence rates and control of asthma, but the expression patterns of estrogen receptor variants and estrogen function in the lung are not well established. We investigated the expression of major estrogen receptor variants occurring naturally and after the development of allergen-induced airway hyperreactivity in a murine model of allergic asthma, along with the role of estrogen signaling in small-airway ciliary motion and smooth muscle contraction. Female BALB/c mice were sensitized with ovalbumin, and estrogen receptor expression patterns were examined by immunofluorescence and Western blot analysis. Time-lapse video and photodiode-based displacement measurement systems were used to assess the effects of estrogen signaling on airway ciliary beat frequency and smooth muscle contraction. We found that a novel variant of estrogen receptor (ER)–α, ER-α36, is expressed in airway epithelial and smooth muscle cells. ER-α36 was predominately localized on the plasma membranes of airway cells. After sensitization to allergen, the expression levels of ER-α36 increased significantly (P < 0.01), whereas the expression of ER-β and ER-α66 did not significantly change. Estrogen treatment in vitro resulted in a rapid increase in airway cilia motion in a dose-dependent fashion, but did not exert any effect on airway smooth muscle contraction. We speculate that the up-regulation of estrogen receptor expression associated with allergen-induced airway hyperresponsiveness may constitute a protective mechanism to facilitate the clearance of mucus. The identification and localization of specific estrogen receptor subtypes in the lung could lead to newer therapeutic avenues aimed at addressing sex differences of asthma susceptibility.
- 1 November 2011
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 45 (5) , 1084-1089
Expression and Function of a Novel Variant of Estrogen Receptor–α36 in Murine Airways
Evidence suggests that estrogen signaling is involved in sex differences in the prevalence rates and control of asthma, but the expression patterns of estrogen receptor variants and estrogen function in the lung are not well established. We investigated the expression of major estrogen receptor variants occurring naturally and after the development of allergen-induced airway hyperreactivity in a murine model of allergic asthma, along with the role of estrogen signaling in small-airway ciliary motion and smooth muscle contraction. Female BALB/c mice were sensitized with ovalbumin, and estrogen receptor expression patterns were examined by immunofluorescence and Western blot analysis. Time-lapse video and photodiode-based displacement measurement systems were used to assess the effects of estrogen signaling on airway ciliary beat frequency and smooth muscle contraction. We found that a novel variant of estrogen receptor (ER)–α, ER-α36, is expressed in airway epithelial and smooth muscle cells. ER-α36 was predominately localized on the plasma membranes of airway cells. After sensitization to allergen, the expression levels of ER-α36 increased significantly (P < 0.01), whereas the expression of ER-β and ER-α66 did not significantly change. Estrogen treatment in vitro resulted in a rapid increase in airway cilia motion in a dose-dependent fashion, but did not exert any effect on airway smooth muscle contraction. We speculate that the up-regulation of estrogen receptor expression associated with allergen-induced airway hyperresponsiveness may constitute a protective mechanism to facilitate the clearance of mucus. The identification and localization of specific estrogen receptor subtypes in the lung could lead to newer therapeutic avenues aimed at addressing sex differences of asthma susceptibility.
- 1 October 2011
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 107 (4) , 364-370
Nasal carbon dioxide for the symptomatic treatment of perennial allergic rhinitis
- 1 October 2011
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 107 (4) , 364-370
Nasal carbon dioxide for the symptomatic treatment of perennial allergic rhinitis
- 1 January 2011
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 127 (1) , 8-15
Future forms of immunotherapy
- 1 January 2011
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 127 (1) , 8-15
Future forms of immunotherapy
- Open Access
- 1 January 2010
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 2 (4) , 228-234
Immunomodulators for Asthma
Dimov VV, et al. Allergy Asthma Immunol Res. 2010 Oct;2(4):228-234. http://dx.doi.org/10.4168/aair.2010.2.4.228
- 1 January 2010
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 2 (4) , 228-234
Open AccessImmunomodulators for Asthma
Dimov VV, et al. Allergy Asthma Immunol Res. 2010 Oct;2(4):228-234. http://dx.doi.org/10.4168/aair.2010.2.4.228
- 13 October 2009
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 9 (6) , 475-483
Immunomodulators in asthma therapy
New developments in the field of allergy and immunology have yielded a variety of novel therapeutic approaches in recent years, and more agents are at the clinical trial stage. Among the therapeutic approaches discussed in this review are Toll-like receptor agonists, immunostimulatory oligodeoxynucleotides, orally and parenterally administered cytokine blockers, and specific cytokine receptor antagonists. Transcription factor modulators targeting syk kinase, peroxisome proliferator-activated receptor-γ, and nuclear factor-κB are also being evaluated in the treatment of asthma. The anti-IgE monoclonal antibody omalizumab has established effectiveness in patients with allergic asthma, but the criteria for selecting patients who are most likely to benefit from it are less clear. This review summarizes data from human clinical trials with immunomodulators to discuss the rationale for their use, their efficacy, and adverse events associated with them.
- 13 October 2009
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 9 (6) , 475-483
Immunomodulators in asthma therapy
New developments in the field of allergy and immunology have yielded a variety of novel therapeutic approaches in recent years, and more agents are at the clinical trial stage. Among the therapeutic approaches discussed in this review are Toll-like receptor agonists, immunostimulatory oligodeoxynucleotides, orally and parenterally administered cytokine blockers, and specific cytokine receptor antagonists. Transcription factor modulators targeting syk kinase, peroxisome proliferator-activated receptor-γ, and nuclear factor-κB are also being evaluated in the treatment of asthma. The anti-IgE monoclonal antibody omalizumab has established effectiveness in patients with allergic asthma, but the criteria for selecting patients who are most likely to benefit from it are less clear. This review summarizes data from human clinical trials with immunomodulators to discuss the rationale for their use, their efficacy, and adverse events associated with them.
- Open Access
- 1 October 2009
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 124 (4) , 665-670
Recommendations for appropriate sublingual immunotherapy clinical trials
- 1 October 2009
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 124 (4) , 665-670
Open AccessRecommendations for appropriate sublingual immunotherapy clinical trials